ACIU
$8.98
AC Immune S.A.
$.03
.34%
ACIU
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.24)
Revenue:  $0.90 Mil
Wednesday
Nov 4
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ACIU reports earnings?
Beat
Meet
Miss

Where is ACIU's stock price going from here?
Up
Flat
Down
Stock chart of ACIU
Analysts
Summary of analysts' recommendations for ACIU
Score
Grade
Pivots
Resistance
$9.32
$9.16
$9.07

$8.90

Support
$8.81
$8.65
$8.56
Tweet
Growth
Description
AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland.